Urinary Retention Postoperative Clinical Trial
Official title:
Effect of Phenazopyridine on Prolapse Surgery Voiding Trials
To determine if phenazopyridine reduces the rate of postoperative urinary retention after pelvic organ prolapse surgery.
Several tools can be used to evaluate for ureteral patency during urogynecologic procedures.
Typically, surgeons use urine dyes such as methylene blue, indigotindisulfonate sodium, or
phenazopyridine, with the latter being restricted to oral administration. However in June
2014, the two U.S. manufacturers of indigotindisulfonate sodium stopped producing the
medication and there is no prospect that it will be returning soon. Phenazopyridine is an
over-the-counter medication (Azo-Gesic, Baridium, Urinary Pain Relief) that has been used
safely for decades as a bladder analgesic and taints the urine orange.
Over the past few months, increasing evidence suggests that phenazopyridine may reduce
transient postoperative urinary retention. Transient urinary retention is common after
urogynecologic surgery and is assessed postoperatively by performing a void trial (VT) prior
to discharge. In a study designed to determine the time from administration of oral
phenazopyridine to visualize dye from the ureters, Propst et al incidentally found that 38%
of patients (19 of 49) failed postoperative VTs without phenazopyridine, but only 19% (9 of
47) failed with phenazopyridine, p=0.04. Most recently, a study by Duenas-Garcia et al
designed to examine local anesthetics and urinary retention in subjects undergoing
midurethral slings found that phenazopyridine decreased the VT failure rate from 30% to 8%
(5). The investigators hypothesize that giving a dose of phenazopyridine the morning after
surgery will significantly reduce the rate of postoperative urinary retention in women
undergoing prolapse repair.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05794503 -
Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex
|
Early Phase 1 | |
Active, not recruiting |
NCT04010656 -
Optimization of Spontaneous Postoperative Trial of Void Among Women
|
N/A | |
Recruiting |
NCT04597372 -
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
|
Phase 2 | |
Not yet recruiting |
NCT06344884 -
Early Patient Removal of Urinary Catheters After Urogynecologic Surgery
|
N/A | |
Recruiting |
NCT04707001 -
Urinary Retention After Arthroplasty
|
N/A | |
Recruiting |
NCT06241703 -
Effect of ICCAUT Strategy on Postoperative Urinary Dysfunction After Radical Rectal Cancer Surgery
|
N/A | |
Terminated |
NCT05353400 -
At Home Early vs. Delayed Catheter Removal Following Failed Postoperative Voiding Trial: a Randomized Trial
|
N/A | |
Completed |
NCT03818321 -
Urinary Track Infection Prevention After Urogynecological Surgery
|
Phase 2 | |
Not yet recruiting |
NCT06262048 -
Prevention of Post Operative Urinary Retention After Thoracic Surgery Trial
|
Phase 2 | |
Recruiting |
NCT05020613 -
Early and Late Removal of the Urinary Catheter After Rectum Resection
|
N/A | |
Completed |
NCT03071211 -
Catheter Management After Pelvic Reconstructive Surgery
|
N/A | |
Recruiting |
NCT05249192 -
Immediate Versus Early (24-hours) Urinary Catheter Removal After Elective Minimally Invasive Colonic Resection
|
N/A | |
Completed |
NCT04783012 -
Patient Removal of Catheters After Urogynecologic Surgery
|
N/A | |
Recruiting |
NCT04465578 -
Incidence of Short-term Urinary Retention After Fascial Retropubic Sling: Prospective and Randomized Analysis.
|
N/A | |
Completed |
NCT05108506 -
Strict Need to Void After Same-day Discharge, Non-urogynecologic, Minimally Invasive Hysterectomy
|
N/A | |
Enrolling by invitation |
NCT05887375 -
Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery
|
Phase 4 | |
Recruiting |
NCT03808155 -
Prevention of Postoperative Urinary Retention With Treatment of Tamsulosin 5 Days Prior to Lower Limb Arthroplasty
|
Phase 4 | |
Completed |
NCT04859660 -
Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy
|
Phase 2 |